AlzeCure Pharma AB (OSTO:ALZCUR) Common Stock : kr2.15 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AlzeCure Pharma AB Common Stock?

AlzeCure Pharma AB's quarterly common stock stayed the same from Dec. 2023 (kr1.55 Mil) to Mar. 2024 (kr1.55 Mil) but then increased from Mar. 2024 (kr1.55 Mil) to Jun. 2024 (kr2.15 Mil).

AlzeCure Pharma AB's annual common stock increased from Dec. 2021 (kr0.94 Mil) to Dec. 2022 (kr1.27 Mil) and increased from Dec. 2022 (kr1.27 Mil) to Dec. 2023 (kr1.55 Mil).

AlzeCure Pharma AB Common Stock Historical Data

The historical data trend for AlzeCure Pharma AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB Common Stock Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.94

1.27

1.55

AlzeCure Pharma AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Common Stock	Get a 7-Day Free Trial															1.55	1.55	1.55	1.55	2.15

AlzeCure Pharma AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (OSTO:ALZCUR) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

AC6:Germany

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines